For a succinct analysis of 1H 2024 venture investment and exit activity in life sciences and health care, take a look at HSBC’s Venture Healthcare Report, Shake it off: HSBC Innovation Banking Analysis, 1H 2024. Lead author Jonathan Norris and his team analyze early stage, venture deals, private M&A and IPO activity in Healthtech, Med Device, Biopharma, and Dx/Tools, in both the United States and Europe. The Report also provides a deep dive into growth and investment in computational biology.
Several key findings of the Report are:
- 1H 2024 investments in Healthtech reversed the 2023 decline with deal activity rising each quarter. The sector also experienced a surge in earlier-stage deals.
- Med device investments are reported to remain stable in large part to an increase in first-financing deals and dollars in 2Q 2024. An increase in early-stage investments in deals requiring robust clinical trials, particularly in neurology.
- For Biopharma, the Report highlights exists and a strong M&A market for growth in the sector. Investment in Biopharma reportedly increased by 35%, and there were 51 private deals exceeding $100 million.
- Dx/Tools sector experienced a decline in first-financing deals. A resurgence of growth investors for companies reaching commercialization provided a bright spot for this sector. Early-stage valuations are reported to remain strong but companies with “lofty” valuations from 2020-2021 experienced down or flat rounds.
The Report summarizes that 1H 2024 experienced increased investment across every analyzed sector with numerous investor-led financings. IPO interest increased in Biopharma as well as high deal-value private M&A.
Author(s)
Related Insights
September 22, 2026
Labor & Employment Law Perspectives
Risk Considerations As EEOC Moves To Ax Data Reports
On July 23, the U.S. Equal Employment Opportunity Commission published a proposed rule to rescind regulations requiring EEO-1 Component 1 reports and other workforce demographic reports and related recordkeeping.[1]
September 21, 2026
Innovative Technology Insights
Can Patent Filings Help Physical AI Companies Raise Capital?
For autonomous systems and physical AI companies, patent cadence can be part of the fundraising story when it maps to defensible shipped technology. This article examines the latest data on patent-funding correlation and translates it from the AV sector to the broader physical AI market.
September 21, 2026
Foley Ignite
Private Equity's Hard Year Has Real Openings
War in the Gulf, an oil spike, rate risk and an AI shock that erased $285 billion of software value in a day have battered sponsors in 2026. Capital is still flowing to firms that return cash — and the law has moved mostly in their favor.